asco

Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as Myelosuppression NEW HAVEN, Conn., May 25, 2023…

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD) 18-month follow-up of patients in phase 2 study shows continued…

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based…

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25,…

SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc.…

<!-- Name:DistributionId Value:8751346 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8751447 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

Additional findings from G-MINOR trial reinforce clinical utility of Veracyte’s Decipher Prostate Genomic Classifier SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced new data being presented this week…

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the development of therapies for cancer and autoimmune diseases, announced today that the latest clinical result of FGFR…